ABSTRACT
AIM: Ischemic stroke (IS) is multifactorial disease and therefore different genes and proteins play a role in its development. Haptoglobin (Hp) removes free hemoglobin and protects from iron-induced oxidative damage, inflammatory response, atherosclerosis and cerebrovascular diseases. The aim of this study was to investigate Hp genetic variants in patients with carotid atherosclerotic lesions and IS. MATERIAL AND METHODS: A total of 121 subjects with IS participated in the study, 81 male and 40 female. RESULTS: Among 121 patients with IS, 79 had diffuse atherosclerotic plaques and stenosis. Hp genotype was statistically significantly associated with CDFI neck carotid artery stenosis findings (p = 0.006). Patients with Hp1-2 genotype had statistically significantly larger odds for atherosclerotic changes compared to those with Hp1-1 genotype, as well as those with Hp2-2 genotype. CONCLUSION: This study has shown an association of the Hp2-2 genotype and atherosclerosis in patients with IS, indicating Hp2-2 genotype as a genetic biomarker for precision medicine and personalized healthcare.
Subject(s)
Atherosclerosis/genetics , Brain Ischemia/genetics , Haptoglobins/genetics , Carotid Stenosis/genetics , Female , Genotype , Haptoglobins/metabolism , Humans , Male , Middle Aged , Plaque, Atherosclerotic/genetics , Polymorphism, Genetic/genetics , Risk Factors , Stroke/complications , Stroke/geneticsABSTRACT
PURPOSE: To assess the usefulness of limbal-conjunctival autograft transplantation (LCAT) for the treatment of recurrent pterygium. PATIENTS AND METHODS: Seventeen eyes with advanced recurrent pterygium underwent LCAT All had already been treated at least twice either by simple excision (n=15) or by conjunctival rotation autograft (n=2). Three eyes (17.65%) had symblepharon at the time of surgery, so LCAT was combined with amniotic membrane transplantation. The autograft was taken from the supero-lateral part of the same eye and transferred to the area where the pterygium had been excised. RESULTS: During 6-18 months of follow-up no postoperative complications occurred. In 15 eyes (88.24%) no pterygium recurrence was recorded; recurrence occurred in two eyes (11.76%) after 8 and 5 months. In three eyes with a combined symblepharon formation, remission of both pterygium and symblepharon growth was obtained. CONCLUSIONS: LCAT seems to be a promising and safe procedure for recurrent pterygium.
Subject(s)
Conjunctiva/transplantation , Epithelium, Corneal/transplantation , Limbus Corneae/cytology , Pterygium/surgery , Adult , Amnion/transplantation , Female , Humans , Male , Middle Aged , Postoperative Complications , Recurrence , Stem Cells/cytology , Transplantation, Autologous , Treatment OutcomeABSTRACT
The objective of this pilot study was to examine the usefulness of limbal autograft transplantation (LCAT) in the treatment of recurrent pterygium. Eleven eyes with advanced recurrent pterygium underwent LCAT. All eyes were previously treated at least two times either by simple excision (10) or conjunctival rotation autograft (1). In two eyes (18.18%) symblepharon was present at the time of surgery, therefore LCAT was combined with amniotic membrane transplantation. Limbal-conjunctival autograft was taken from supero-lateral part of the same eye and transferred to the area where pterygium was excised. No intraoperative complications occurred. In ten eyes (90.9%) no pterygium recurrence was recorded during the follow-up time, and one (9.1%) recurrence was recorded after 5 months. In two eyes with combined symblepharon formation remission of both pterygium and symblepharon growth was obtained. LCAT proved to be a promising and safe procedure in recurrent pterygium treatment.
